Trial Profile
The Effect of Switching Therapy to Pegaptanib in Eyes with the Persistent Cases of Exudative Age-related Macular Degeneration.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 May 2016
Price :
$35
*
At a glance
- Drugs Pegaptanib (Primary) ; Ranibizumab
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 06 Dec 2015 New trial record